Pazopanib is a new oral angiogenesis inhibitor developed by GlaxoSmithKline that can interfere with the neoangiogenesis required for the survival and growth of intractable tumors. It targets the vascular endothelial growth factor receptor (VEGFR) and acts by inhibiting the neoangiogenesis of tumor blood supply. It is suitable for the treatment of advanced renal cell carcinoma (a type of renal cancer in which cancer cells are found in renal tubules), soft tissue sarcoma (STS), epithelial ovarian cancer and non-small cell lung cancer (NSCLC).
Manufacturing
